Applications of single-chain variable fragment antibodies in therapeutics and diagnostics

Weisser, Nina E.; Hall, J. Christopher

doi:10.1016/j.biotechadv.2009.04.004

Cited by 225 publications

(183 citation statements)

References 227 publications

Supporting

Mentioning

175

Contrasting

Unclassified

Order By: Relevance

“…Sequence variability is concentrated in these regions, and loop formation occurs here. The remaining areas of the VH and VL domains show less variation and comprise the framework (Fr) regions which structurally support the loops [21].…”

Section: Antibodies and Their Fragmentsmentioning

confidence: 99%

“…While mAbs are effective therapeutic agents when the antigenic target is well-defined and accessible, such as in some cancers and autoimmune diseases, many diseases offer less accessible (e.g., intracellular), cryptic, or hypoallergenic targets [40,62]. In such circumstances, antibody fragments may provide advantages due to their smaller size and structure, and the ease with which they can be produced and genetically modified [11,21,27,47,[63][64][65][66]. Ab-fragment-related biomedical applications include tumor treatment and imaging [67], viral replication suppression [68][69][70], toxin and venom neutralization [41,71], and receptor blockage [36,72].…”

Section: Mabs and Their Fragments As Therapeutic Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Antibody Fragments and Their Purification by Protein L Affinity Chromatography

Rodrigo¹,

Gruvegard²,

Alstine

2015

Antibodies

View full text Add to dashboard Cite

Antibodies and related proteins comprise one of the largest and fastest-growing classes of protein pharmaceuticals. A majority of such molecules are monoclonal antibodies; however, many new entities are antibody fragments. Due to their structural, physiological, and pharmacological properties, antibody fragments offer new biopharmaceutical opportunities. In the case of recombinant full-length antibodies with suitable Fc regions, two or three column purification processes centered around Protein A affinity chromatography have proven to be fast, efficient, robust, cost-effective, and scalable. Most antibody fragments lack Fc and suitable affinity for Protein A. Adapting proven antibody purification processes to antibody fragments demands different affinity chromatography. Such technology must offer the unit operation advantages noted above, and be suitable for most of the many different types of antibody fragments. Protein L affinity chromatography appears to fulfill these criteria-suggesting its consideration as a key unit operation in antibody fragment processing.

show abstract

Section: Antibodies and Their Fragmentsmentioning

confidence: 99%

Section: Mabs and Their Fragments As Therapeutic Agentsmentioning

confidence: 99%

Antibody Fragments and Their Purification by Protein L Affinity Chromatography

Rodrigo¹,

Gruvegard²,

Alstine

2015

Antibodies

View full text Add to dashboard Cite

show abstract

“…Le et al [19] proposed that the range of the length of link peptides was within 6-27 amino acids. Weisser et al [20] found that when the number of amino acids of linkers was 15, that is, n=3 in (Gly 4 Ser) n , the affinities, activities and the other aspects could reach a satisfactory level. All these were in an agreement with the results of the present study.…”

Section: Discussionmentioning

confidence: 99%

Study on the Relationship between the Structure and Functions of Antihuman Cervical Cancer Single-chain Antibody and the Lengths of Linkers

Zhang¹

2014

J Proteomics Bioinform

View full text Add to dashboard Cite

IntroductionCervical cancer (CC) is a malignant tumor occurred in the uterus vagina and cervical canals. It is one of the most common gynecological malignancies [1] and the incidence takes the second place among gynecologic oncology. Each year, there are about 530,000 new cervical cancer cases worldwide, of which 85% occur in developing countries, and cervical cancer is one of the main causes of death of women in developing countries [2][3][4]. Therefore, how to improve the long-term survival of patients with cervical cancer is an important issue in clinical and basic research.With constantly thorough study of molecular biology, genetically engineered antibody has been widely used in the diagnoses and treatments of diseases. It has great potential in the diagnosis and treatment of malignancy. Single-chain variable fragment (ScFv) is a small molecule antibody that has intact antigen-binding site. Compared with the defects of monoclonal antibody, such as large amount of antibody molecules, low penetrating ability, low clearance rate of blood and low ration of tumor blood [5], ScFv has advantages, such as small amount of antibody molecules, high penetrating ability, low immunogenicity and easy to mass production. It can also neutralize virus and toxin to give play to immunization in cells and be guided carrier. However, studies about the application of ScFv in CC treatment are rarely reported. As a result, it is of particular significance to conduct an in-depth research on the single-chain antibody of CC, which would provide a new direction of treating CC.ScFv is recombinant protein linked by a length of connecting peptide through VH and VL. Different lengths of linkers among chains have different influence on the active of single-chain antibody, so an insight into the impact of different lengths of linkers among chains on the biological activity of single-chain antibody has great significance in the establishment of single-chain antibody and screening of linkers among chains. By using the bioinformatics method, this study compared the impact of different linkers among chains on the structures and functions of single-chain antibody of CC from the aspects of protein tertiary structure, aiming to providing new ideas of the screening of interchain linker length of CC and the establishment of single-chain antibody, and also providing some theoretical bases for the targeted therapy of CC. Materials and Methods Experimental materialsThe amino acid sequences of single-chain antibody VH and VL of CC were from the articles related to researches of the anti-human cervical cancer written by Wang et al. [6]. Hela human cervical epithelial cell line was preserved in our lab. We ourselves constructed the general expression vector of single-chain antibody of connecting peptide with different length, expressed by HB2151 expressing system, AbstractBackground: This study aimed to find the linker length with minimal impact among chains to fight against the structure and function of cervical cancer single-chain antibody.

show abstract

“…1 The most widespread method of generating such miniantibodies is phage-display technology. 2 Miniantibodies generated after three or four rounds of selection on the antigen can specifically recognize the target antigen in a mixture of homologous antigens.…”

Section: Introductionmentioning

confidence: 99%